Ipsos Launches Oncology MDx Lab Mapping Study

Ipsos Healthcare has announced the US launch of a new study, Oncology Molecular Diagnostics (MDx) Lab Mapping, which delivers a picture of the laboratories involved in cancer biomarker testing.

Data collected from the syndicated study will enable subscribers to map out the type, structure and workforce of the laboratories; capture details around testing volume and tissue flow; and break down the volume of testing carried out by cancer type and methodology of biomarker testing.

The study will shortly be rolled out in the EU5 (France, Germany, Italy, Spain and the UK), and in Australia and China.

Pieter De Richter, Head of the division's Molecular Diagnostics Portfolio, says: 'Given the complexity of this industry and the great variety of different commercial and non-commercial laboratory types, this provides an invaluable tool for companies seeking to plan and implement a companion diagnostics launch strategy.'

Web site: www.ipsos.com .